Your browser doesn't support javascript.
loading
Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression.
Ashrafizadeh, Milad; Mirzaei, Sepideh; Gholami, Mohammad Hossein; Hashemi, Farid; Zabolian, Amirhossein; Raei, Mehdi; Hushmandi, Kiavash; Zarrabi, Ali; Voelcker, Nicolas H; Aref, Amir Reza; Hamblin, Michael R; Varma, Rajender S; Samarghandian, Saeed; Arostegi, I J; Alzola, M; Kumar, Alan Prem; Thakur, Vijay Kumar; Nabavi, Noushin; Makvandi, Pooyan; Tay, Franklin R; Orive, Gorka.
Afiliación
  • Ashrafizadeh M; Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanli, Tuzla, 34956, Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956, Istanbul, Turkey.
  • Mirzaei S; Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.
  • Gholami MH; Faculty of Veterinary Medicine, Kazerun Branch, Islamic Azad University, Kazerun, Iran.
  • Hashemi F; Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
  • Zabolian A; Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Raei M; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Hushmandi K; Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
  • Zarrabi A; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956, Istanbul, Turkey.
  • Voelcker NH; Monash Institute of Pharmaceutical Sciences, Parkville, Victoria 3052, Australia; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Clayton, Victoria, 3168, Australia; Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, 151 Wellin
  • Aref AR; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Translational Sciences, Xsphera Biosciences Inc., Boston, MA, USA.
  • Hamblin MR; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa; Radiobiology Research Center, Iran University of Medical Science, Tehran, Iran.
  • Varma RS; Regional Center of Advanced Technologies and Materials, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic.
  • Samarghandian S; Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Arostegi IJ; NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
  • Alzola M; NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
  • Kumar AP; NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; Cancer Science Institute of Singapore and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
  • Thakur VK; Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), Kings Buildings, Edinburgh EH9 3JG, UK; Department of Mechanical Engineering, School of Engineering, Shiv Nadar University, Uttar Pradesh 201314, India.
  • Nabavi N; Department of Urological Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H3Z6, Canada.
  • Makvandi P; Istituto Italiano di Tecnologia, Center for Materials Interfaces, viale Rinaldo Piaggio 34, 56025 Pontedera, Pisa, Italy. Electronic address: Pooyan.makvandi@iit.it.
  • Tay FR; The Graduate School, Augusta University, Augusta, GA, USA. Electronic address: ftay@augusta.edu.
  • Orive G; NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Impla
Carbohydr Polym ; 272: 118491, 2021 Nov 15.
Article en En | MEDLINE | ID: mdl-34420747
ABSTRACT
An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Ácido Hialurónico Límite: Animals / Humans Idioma: En Revista: Carbohydr Polym Año: 2021 Tipo del documento: Article País de afiliación: Turquía
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Ácido Hialurónico Límite: Animals / Humans Idioma: En Revista: Carbohydr Polym Año: 2021 Tipo del documento: Article País de afiliación: Turquía